DRESDEN, Germany, August 22, 2019 / B3C newswire / -- Due to their high accessibility and extensive beneficial properties, human Mesenchymal Stem Cells (hMSC) offer exciting promises in a plethora of applications in regenerative medicine, particularly in cell-based therapies. The major challenge of hMSC-based therapy is the large-scale expansion of cells in order to achieve the cell numbers necessary for therapeutic treatment. Currently, bovine-derived fetal calf serum and human plasma-derived fibronectin are commonly used in hMSC culture. These biological extracts frequently reduce experimental reproducibility, and represent a liability for manufacturers of hMSC. To increase lot-to-lot consistency and eliminate the risk of transmission of xenogenic infectious agents, defined cell culture conditions including media and extracellular matrix mimetic coatings are essential.
denovoMATRIX has now introduced a ready-to-use coating composed of chemically defined components. The new product - termed myMATRIX MSC - promotes adhesion, proliferation and high viability of hMSC. According to the manufacturer, this novel surface supports long-term expansion of hMSCs over 10 passages and more than 25 population doublings. Furthermore, myMATRIX MSC enables expansion of hMSC in both serum-free and xeno-free media conditions.
For high resolution please click the image.
Read the application note about myMATRIX hMSC, including detailed expansion analysis of hMSC here.
Vision for the future?
Enabling animal-component free processes for large-scale manufacturing of hMSC.
The field of cell-based therapies just took a step closer.
denovoMATRIX develops and manufactures biomimetic coatings for the cultivation of human stem cells. Our focus is on enabling culture conditions for stem cells closer to the natural conditions found in the body. Our products offer a biologically relevant solution, which is both chemically defined, and modular for adapting to specific applications. Our vision is to enable human biology in vitro, beginning with Life Science research and onwards to cell therapies of the future.
Published by B3C newswire and shared through Newronic®